ReviewCureus2026

Health-Related Quality of Life and Cost-Effectiveness of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Monotherapy in Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Systematic Review.

Subodh Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.